Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Paratus Investment
Deal Size : $14.5 million
Deal Type : Series B Financing
MicrobiotiX Finalizes KRW 20 Billion Series B, Securing Korea's First Bacteriophage Trial
Details : The proceeds will be used to begin the first-ever human clinical trial of phage therapy in Korea.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
September 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Paratus Investment
Deal Size : $14.5 million
Deal Type : Series B Financing